StreetInsider.com News Articles

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Wed, 19 Feb 2025 05:00:00 -0400

Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at the end of last year with the official notification received by Medigene in 2025.

“We have built a

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Wed, 19 Feb 2025 05:00:00 -0400

“We have built a

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Wed, 19 Feb 2025 05:00:00 -0400

“We have built a

Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.

Wed, 19 Feb 2025 05:00:00 -0400

“We have built a

Medigene AG announces closing of its first SEPA tranche

Mon, 03 Feb 2025 12:00:00 -0400

Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024.

The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average price of the Medigene share on the Xetra exchange

Medigene AG announces closing of its first SEPA tranche

Mon, 03 Feb 2025 12:00:00 -0400

The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average price of the Medigene share on the Xetra exchange

Medigene AG announces closing of its first SEPA tranche

Mon, 03 Feb 2025 12:00:00 -0400

The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average price of the Medigene share on the Xetra exchange

Medigene AG announces closing of its first SEPA tranche

Mon, 03 Feb 2025 12:00:00 -0400

The subscription price was set at EUR 1.70 and is equal to 95% of the average of the volume-weighted average price of the Medigene share on the Xetra exchange

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Mon, 09 Dec 2024 05:00:00 -0400

Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the selection of Kirsten rat sarcoma viral oncogene homologue (KRAS) G12V, in the context of HLA*A11, as the initial target for the co-development of T cell receptor-guided T cell engagers (TCR-TCEs) with WuXi Biologics.

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Mon, 09 Dec 2024 05:00:00 -0400

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Mon, 09 Dec 2024 05:00:00 -0400

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

Mon, 09 Dec 2024 05:00:00 -0400

The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Tue, 26 Nov 2024 08:00:00 -0400

Planegg/Martinsried, November 26, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today an update of its corporate strategy to refocus its capital allocation on R&D programs with highest potential for return on invested capital resulting in an organizational realignment. This strategic refocus supports the Company’s short-, mid-, and long-term vision of generating optimal 3S (sensitive, specific and safe) TCRs for the development of multiple off-the-shelf TCR-guided therapies while creating value for patients, investors

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Tue, 26 Nov 2024 08:00:00 -0400

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Tue, 26 Nov 2024 08:00:00 -0400

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Tue, 26 Nov 2024 08:00:00 -0400

Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024